Exclusive Summary

• - Full-strength portfolio (40/125/500 mg/1 g/2 g) plus ICH Zone IV stability covers ED use to pulse therapy and global tenders.
• - FDA-GMP with US approval and supplier-reported #1 US market share demonstrate quality and large-scale, reliable supply.
• - Broad indications (acute asthma/COPD, anaphylaxis adjunct, MS relapse, SLE/transplant pulses) address >200M respiratory patients plus millions with immune diseases.
• - Long off-patent, widely genericized molecule enables rapid market access and parallel registrations under distribution models.
• - Typically 60–90% cost savings vs originator; multi-strength mix boosts tender win rates and inventory efficiency.